Long-term efficacy of high-dose diltiazem for chronic stable angina pectoris: 16-month serial studies with placebo controls

Michael A. Petru, Michael H. Crawford, Gemma T. Kennedy, K. Wray Amon, Robert A. O'Rourke

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    In order to assess the long-term efficacy of diltiazem for the treatment of angina pectoris, eight patients with chronic stable exertional angina who were previously entered into a 4-month randomized, double-blind placebo controlled study, were studied for an additional 12 months. The patients continued to take diltiazem, 360 mg/day, and underwent treadmill exercise testing after 10 and 16 months of therapy. A single-blind placebo week was introduced after 16 months and a treadmall test was porformed at the end of this week. Diltiazem therapy continued to augment exercise duration until 0.1 mV of ECG ST depression at 10 and 16 months as compared to the final pracebo period: 573 ± 133 (SD) seconds at 10 months; 565 ± 148 seconds at 16 months; vs 431 ± 151 seconds at final placebo (both p < 0.001). Also, the time to angina pectoris was prolonged on diltiazem by 181 seconds at 16 months (p < 0.01) and the total duration of exercise was increased by 101 seconds (p < 0.001) as compared to placebo. In addition, angina frequency decreased from 17 ± 11 attacks/week on placebo to 0.6 ± 0.6 attacks/week during diltiazem therapy at 16 months. Two of the eight paitents noted mild pedal edema, but no other adverse effects were experienced. Thus diltiazem, 360 mg/day, can be an effective single agent for the long-term treatment of chronic stable angina pectoris.

    Original languageEnglish (US)
    Pages (from-to)99-103
    Number of pages5
    JournalAmerican Heart Journal
    Volume109
    Issue number1
    DOIs
    StatePublished - 1985

    Fingerprint

    Stable Angina
    Diltiazem
    Placebos
    Angina Pectoris
    Exercise
    Therapeutics
    Foot
    Edema
    Electrocardiography

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Cite this

    Long-term efficacy of high-dose diltiazem for chronic stable angina pectoris : 16-month serial studies with placebo controls. / Petru, Michael A.; Crawford, Michael H.; Kennedy, Gemma T.; Amon, K. Wray; O'Rourke, Robert A.

    In: American Heart Journal, Vol. 109, No. 1, 1985, p. 99-103.

    Research output: Contribution to journalArticle

    Petru, Michael A. ; Crawford, Michael H. ; Kennedy, Gemma T. ; Amon, K. Wray ; O'Rourke, Robert A. / Long-term efficacy of high-dose diltiazem for chronic stable angina pectoris : 16-month serial studies with placebo controls. In: American Heart Journal. 1985 ; Vol. 109, No. 1. pp. 99-103.
    @article{44ebec68710f4f27b687db8208ae4ef0,
    title = "Long-term efficacy of high-dose diltiazem for chronic stable angina pectoris: 16-month serial studies with placebo controls",
    abstract = "In order to assess the long-term efficacy of diltiazem for the treatment of angina pectoris, eight patients with chronic stable exertional angina who were previously entered into a 4-month randomized, double-blind placebo controlled study, were studied for an additional 12 months. The patients continued to take diltiazem, 360 mg/day, and underwent treadmill exercise testing after 10 and 16 months of therapy. A single-blind placebo week was introduced after 16 months and a treadmall test was porformed at the end of this week. Diltiazem therapy continued to augment exercise duration until 0.1 mV of ECG ST depression at 10 and 16 months as compared to the final pracebo period: 573 ± 133 (SD) seconds at 10 months; 565 ± 148 seconds at 16 months; vs 431 ± 151 seconds at final placebo (both p < 0.001). Also, the time to angina pectoris was prolonged on diltiazem by 181 seconds at 16 months (p < 0.01) and the total duration of exercise was increased by 101 seconds (p < 0.001) as compared to placebo. In addition, angina frequency decreased from 17 ± 11 attacks/week on placebo to 0.6 ± 0.6 attacks/week during diltiazem therapy at 16 months. Two of the eight paitents noted mild pedal edema, but no other adverse effects were experienced. Thus diltiazem, 360 mg/day, can be an effective single agent for the long-term treatment of chronic stable angina pectoris.",
    author = "Petru, {Michael A.} and Crawford, {Michael H.} and Kennedy, {Gemma T.} and Amon, {K. Wray} and O'Rourke, {Robert A.}",
    year = "1985",
    doi = "10.1016/0002-8703(85)90422-3",
    language = "English (US)",
    volume = "109",
    pages = "99--103",
    journal = "American Heart Journal",
    issn = "0002-8703",
    publisher = "Mosby Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Long-term efficacy of high-dose diltiazem for chronic stable angina pectoris

    T2 - 16-month serial studies with placebo controls

    AU - Petru, Michael A.

    AU - Crawford, Michael H.

    AU - Kennedy, Gemma T.

    AU - Amon, K. Wray

    AU - O'Rourke, Robert A.

    PY - 1985

    Y1 - 1985

    N2 - In order to assess the long-term efficacy of diltiazem for the treatment of angina pectoris, eight patients with chronic stable exertional angina who were previously entered into a 4-month randomized, double-blind placebo controlled study, were studied for an additional 12 months. The patients continued to take diltiazem, 360 mg/day, and underwent treadmill exercise testing after 10 and 16 months of therapy. A single-blind placebo week was introduced after 16 months and a treadmall test was porformed at the end of this week. Diltiazem therapy continued to augment exercise duration until 0.1 mV of ECG ST depression at 10 and 16 months as compared to the final pracebo period: 573 ± 133 (SD) seconds at 10 months; 565 ± 148 seconds at 16 months; vs 431 ± 151 seconds at final placebo (both p < 0.001). Also, the time to angina pectoris was prolonged on diltiazem by 181 seconds at 16 months (p < 0.01) and the total duration of exercise was increased by 101 seconds (p < 0.001) as compared to placebo. In addition, angina frequency decreased from 17 ± 11 attacks/week on placebo to 0.6 ± 0.6 attacks/week during diltiazem therapy at 16 months. Two of the eight paitents noted mild pedal edema, but no other adverse effects were experienced. Thus diltiazem, 360 mg/day, can be an effective single agent for the long-term treatment of chronic stable angina pectoris.

    AB - In order to assess the long-term efficacy of diltiazem for the treatment of angina pectoris, eight patients with chronic stable exertional angina who were previously entered into a 4-month randomized, double-blind placebo controlled study, were studied for an additional 12 months. The patients continued to take diltiazem, 360 mg/day, and underwent treadmill exercise testing after 10 and 16 months of therapy. A single-blind placebo week was introduced after 16 months and a treadmall test was porformed at the end of this week. Diltiazem therapy continued to augment exercise duration until 0.1 mV of ECG ST depression at 10 and 16 months as compared to the final pracebo period: 573 ± 133 (SD) seconds at 10 months; 565 ± 148 seconds at 16 months; vs 431 ± 151 seconds at final placebo (both p < 0.001). Also, the time to angina pectoris was prolonged on diltiazem by 181 seconds at 16 months (p < 0.01) and the total duration of exercise was increased by 101 seconds (p < 0.001) as compared to placebo. In addition, angina frequency decreased from 17 ± 11 attacks/week on placebo to 0.6 ± 0.6 attacks/week during diltiazem therapy at 16 months. Two of the eight paitents noted mild pedal edema, but no other adverse effects were experienced. Thus diltiazem, 360 mg/day, can be an effective single agent for the long-term treatment of chronic stable angina pectoris.

    UR - http://www.scopus.com/inward/record.url?scp=0022179219&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0022179219&partnerID=8YFLogxK

    U2 - 10.1016/0002-8703(85)90422-3

    DO - 10.1016/0002-8703(85)90422-3

    M3 - Article

    C2 - 3880993

    AN - SCOPUS:0022179219

    VL - 109

    SP - 99

    EP - 103

    JO - American Heart Journal

    JF - American Heart Journal

    SN - 0002-8703

    IS - 1

    ER -